Life expectancy of people with hemophilia in France in 2022.

The life expectancy of adult people with hemophilia has significantly increased thanks to therapeutic advancements, especially after the bloodborne infectious risks were controlled. However, no French data has yet documented this improvement. This study aims to compare the life expectancy of French people with hemophilia to that of the general population. A longitudinal study was conducted on 9,928 people with hemophilia included in the FranceCoag database between 1994 and 2022. Life expectancies were calculated using abridged life tables The life expectancies for people with hemophilia were 66.3 years at age 20 (mild hemophilia = 68.8, moderate = 64.8, severe = 60.4) and 47.5 years at age 40 (mild = 49.2, moderate = 45.9, severe = 42.7). Individuals with mild or moderate hemophilia had higher life expectancies compared to general population (59.8 years at age 20 and 40.7 years at age 40, p < 0.001). Those with severe hemophilia had a similar or slightly higher life expectancy at age 40. The mean differences in LE at ages 20 and 40, compared with the general population, varied markedly by severity, ranging from 0 to 10 years. Taken together, these findings suggest broadly comparable life expectancy in people with hemophilia, although differences remain according to disease severity. This improvement may be attributable both to recent therapeutic innovations and to more frequent and comprehensive medical follow-ups compared to the general population.